Wang Shi-Yuan, Cheng Xiao-Hua, Li Jing-Xin, Li Xi-Yan, Zhu Feng-Cai, Liu Pei
a Department of Epidemiology and Biostatistics; School of Public Health; Southeast University ; Nanjing , Jiangsu , China.
Hum Vaccin Immunother. 2015;11(6):1418-25. doi: 10.1080/21645515.2015.1011996.
Japanese encephalitis virus (JEV), a leading cause of Japanese encephalitis (JE) in children and adults, is a major public health problem in Asian countries. This study reports a meta-analysis of the immunogenicity and safety of vaccines used to protect infants or children from JE. Three types of JE vaccine were examined, namely, Japanese encephalitis live-attenuated vaccine (JEV-L), Japanese encephalitis inactivated vaccine (Vero cell) (JEV-I(Vero)), and Japanese encephalitis inactivated vaccine (primary hamster kidney cell) (JEV-I(PHK)). These vaccines are used to induce fundamental immunity against JE; however, few studies have compared their immunogenicity and safety in infants and young children less than 2 years of age. Data were obtained by searching 5 databases: Web of Science, PubMed, China National Knowledge Infrastructure, the China Wanfang database, and the Cochrane database. Fifteen articles were identified and scored using the Jadad score for inclusion in the meta-analysis. Random effect models were used to calculate the pooled seroconversion rate and adverse reaction rate when tests for heterogeneity were significant. The results showed that the pooled seroconversion rate for JEV-I(PHK) (62.23%) was lower than that for JEV-I(Vero) (86.49%) and JEV-L (83.52%), and that the pooled adverse reaction rate for JEV-L (18.09%) was higher than that for JEV-I(PHK) (10.08%) and JEV-I(Vero) (12.49%). The pooled relative risk was then calculated to compare the seroconversion and adverse reaction rates. The results showed that JEV-I(Vero) and JEV-L were more suitable than JEV-I(PHK) for inducing fundamental immunity to JE in infants and children less than 2 years of age.
日本脑炎病毒（JEV）是儿童和成人患日本脑炎（JE）的主要病因，是亚洲国家的一个重大公共卫生问题。本研究报告了一项关于用于保护婴儿或儿童预防JE的疫苗的免疫原性和安全性的荟萃分析。研究了三种类型的JE疫苗，即日本脑炎减毒活疫苗（JEV-L）、（Vero细胞）日本脑炎灭活疫苗（JEV-I(Vero)）和（原代仓鼠肾细胞）日本脑炎灭活疫苗（JEV-I(PHK)）。这些疫苗用于诱导针对JE的基础免疫；然而，很少有研究比较它们在2岁以下婴幼儿中的免疫原性和安全性。通过检索5个数据库获取数据：科学网、PubMed、中国知网、中国万方数据库和考克兰数据库。使用Jadad评分法对15篇文章进行识别和评分，以纳入荟萃分析。当异质性检验显著时，使用随机效应模型计算合并血清转化率和不良反应率。结果显示，JEV-I(PHK)的合并血清转化率（62.23%）低于JEV-I(Vero)（86.49%）和JEV-L（83.52%），JEV-L的合并不良反应率（18.09%）高于JEV-I(PHK)（10.08%）和JEV-I(Vero)（12.49%）。然后计算合并相对风险以比较血清转化率和不良反应率。结果表明，在2岁以下婴幼儿中，JEV-I(Vero)和JEV-L比JEV-I(PHK)更适合诱导针对JE的基础免疫。
